Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Skywalker OG is an indica-dominant hybrid cannabis strain, resulting from a cross between Skywalker (Mazar x Blueberry) and OG Kush. It is highly regarded in the medical cannabis community for its potent sedative and analgesic effects, attributed to its high tetrahydrocannabinol (THC) content and a specific terpene profile typically rich in myrcene and limonene. The strain functions primarily as a partial agonist at the Cannabinoid Receptor 1 (CB1) and Cannabinoid Receptor 2 (CB2) within the endocannabinoid system, modulating the release of neurotransmitters to alleviate symptoms of chronic pain, insomnia, and anxiety. While not a pharmaceutical product developed through traditional clinical trial pathways, it is widely utilized in jurisdictions where medical cannabis is regulated.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Skywalker OG.